RxDoctor Payments Data

Bobby Peterson, MD

Family Medicine · Escalon, CANPI 1841359171

Payments from drug & device makers

$2,687in general payments, 2019–2025

Across 121 payments — averaging $22.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$916
  • Novo Nordisk$422
  • Bayer$251
  • Lilly USA, LLC$238
  • E.r. Squibb & Sons, L.L.C.$131
  • GSK$129
  • plus $599 from 17 others

What the payments were for

  • Food & beverage$2,687100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,687 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$56,893
Medicare patients
121
Services billed
664

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban94$117,162
OzempicSemaglutide104$116,899
JardianceEmpagliflozin54$58,955
FarxigaDapagliflozin Propanediol37$46,431
InvokanaCanagliflozin11$17,970
Bydureon BciseExenatide Microspheres13$16,395
JanuviaSitagliptin Phosphate16$12,573
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$11,898
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$11,827
TradjentaLinagliptin13$11,066
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen258$6,340
Valsartan141$3,785
Atorvastatin Calcium350$3,534
Levothyroxine Sodium218$3,277
Lantus SolostarInsulin Glargine,hum.Rec.Anlog39$3,198

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$16$117,16294 claims
Novo NordiskOzempic$422$116,899104 claims
Boehringer IngelheimJardiance, Tradjenta$43$70,02167 claims
AstraZenecaFarxiga, Breztri Aerosphere$916$58,32958 claims
MerckJanuvia$35$12,57316 claims
GSKTrelegy Ellipta$129$11,82715 claims
Sanofi-aventis U.S. LLCLantus$40$1,56424 claims
Lilly USA, LLCHumalog$238$1,23321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.

Other family medicine in Escalon

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →